Comprehensive grading of Parkinson’s disease using motor and non-motor assessments: addressing a key unmet need

References

• Chaudhuri KR, Odin P, Antonini A, et al. Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord. 2011;17:717–723.
   PubMed Web of Science ®Google Scholar
• Jellinger K. Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna). 2015;122:1429–1440.
   PubMed Web of Science ®Google Scholar
• Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18:435–450.
   PubMed Web of Science ®Google Scholar
• Titova N, Padmakumar C, Lewis S, et al. Parkinson’s: a syndrome rather than a disease? J Neural Transm. 2017;124:907–914.
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Personalised medicine in Parkinson’s disease: time to be precise. Mov Disord. 2017;32:1147–1154.
   PubMed Web of Science ®Google Scholar
• Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015;14:57–64.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464–474.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord. 2012;27:617–626.
   PubMed Web of Science ®Google Scholar
• Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson’s disease. Mov Disord. 2012;27:54–60.
   PubMed Web of Science ®Google Scholar
• Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015;30:1600–1611.
   PubMed Web of Science ®Google Scholar
• Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745–752.
   PubMed Web of Science ®Google Scholar
• Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–1601.
   PubMed Web of Science ®Google Scholar
• Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123:2297–2305.
   PubMed Web of Science ®Google Scholar
• Lopez IC, Ruiz PJ, Del Pozo SV, et al. Motor complications in Parkinson’s disease: ten year follow-up study. Mov Disord. 2010;25:2735–2739.
   PubMed Web of Science ®Google Scholar
• Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology. 2013;80:800–809.
   PubMed Web of Science ®Google Scholar
• Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30:80–89.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13:217–231.
   PubMed Web of Science ®Google Scholar
• Bjornestad A, Pedersen KF, Tysnes O-B, et al. Clinical milestones in Parkinson’s disease: a 7-year population-based incident cohort study. Parkinsonism Relat Disord. 2017;42:28–33.
   PubMed Web of Science ®Google Scholar
• Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017;374:26–31.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AHV, Martínez-Martín P, et al. Can we improve the holistic assessment of Parkinson’s disease? The development of a non-motor symptom questionnaire and scale for Parkinson’s disease. ACNR. 2004;4:20–25.
   Google Scholar
• Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–923.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007;22:1901–1911.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26:399–406.
   PubMed Web of Science ®Google Scholar
• Kadastik-Eerme L, Rosenthal M, Paju T, et al. Health-related quality of life in Parkinson’s disease: a cross-sectional study focusing on non-motor symptoms. Health Qual Life Outcomes. 2015;13:83.
   PubMed Web of Science ®Google Scholar
• Skorvanek M, Rosenberger J, Minar M, et al. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson’s disease. J Neurol Sci. 2015;353:87–91.
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837–844.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Paz S, et al. Parkinson symptoms and health related quality of life as predictors of costs: a longitudinal observational study with linear mixed model analysis. PLoS One. 2015;10:e0145310.
   PubMed Web of Science ®Google Scholar
• Hassan A, Wu SS, Schmidt P, et al. The profile of long-term Parkinson’s disease survivors with 20 years of disease duration and beyond. J Parkinsons Dis. 2015;5:313–319.
   PubMedGoogle Scholar
• Puschmann A, Brighina L, Markopoulou K, et al. Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: an international consensus statement. Parkinsonism Relat Disord. 2015;21:675–682.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25:704–709.
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri K, Rojo JM, Schapira AH, et al. A proposal for a comprehensive grading of Parkinson’s disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One. 2013;8:e57221.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Sauerbier A, Rojo JM, et al. The burden of non-motor symptoms in Parkinson’s disease using a self-completed non-motor questionnaire: a simple grading system. Parkinsonism Relat Disord. 2015;21:287–291.
   PubMed Web of Science ®Google Scholar
• Collins English Dictionary. [cited 2017 Jul 28]. Available from: https://www.collinsdictionary.com/dictionary/english/grading.
   Google Scholar
• Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976. p. 217–222.
   Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28–37.
   PubMedGoogle Scholar
• Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340:757–763.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Benito-Leon J, Burguera JA, et al. The SCOPA-Motor Scale for assessment of Parkinson’s disease is a consistent and valid measure. J Clin Epidemiol. 2005;58:674–679.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Aarsland D, Fénelon G, et al. Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23:484–500.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Stebbins GT, Chung KA, et al. Which dyskinesia scale best detects treatment response? Mov Disord. 2013;28:341–346.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Alvarez M, et al. Parkinson’s disease severity levels and MDS-Unified Parkinson’s Disease Rating Scale. Parkinsonism Relat Disord. 2015;21:50–54.
   PubMed Web of Science ®Google Scholar
• Okai D, Askey-Jones S, Samuel M, et al. Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson’s disease. Mov Disord. 2015;30:736–739.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rojo-Abuin JM, Rodriguez-Violante M, et al. Analysis of four scales for global severity evaluation in Parkinson’s disease. NPJ Parkinsons Dis. 2016;2:16007.
   PubMed Web of Science ®Google Scholar
• Bump RC, Norton PA, Zinner NR, et al. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. Obstet Gynecol. 2003;102:76–83.
   PubMed Web of Science ®Google Scholar
• Targum SD, Hassman H, Pinho M, et al. Development of a clinical global impression scale for fatigue. J Psychiatr Res. 2012;46:370–374.
   PubMed Web of Science ®Google Scholar
• Agüera-Ortiz L, Montón C, Cuervo J, et al. Adaptation into Spanish of the Clinically Useful Depression Outcome Scale (CUDOS) for assessing major depressive disorder from the patient’s perspective. Actas Esp Psiquiatr. 2013;41:287–300.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Jankovic J, Holds JB, et al. Observational study of incobotulinumtoxinA for cervical dystonia or blepharospasm (XCiDaBLE): interim results for the first 170 subjects with blepharospasm. Tremor Other Hyperkinet Mov (N Y). 2014;4:238.
   PubMedGoogle Scholar
• Ambrosio L, Portillo MC, Rodriguez-Blazquez C, et al. Satisfaction with Life Scale (SLS-6): first validation study in Parkinson’s disease population. Parkinsonism Relat Disord. 2016;25:52–57.
   PubMed Web of Science ®Google Scholar
• Titova N, Qamar MA, Chaudhuri KR. Biomarkers of Parkinson’s disease: an introduction. Int Rev Neurobiol. 2017;132:183–193.
   PubMed Web of Science ®Google Scholar
• Simuni T, Luo ST, Chou KL, et al. Rankin scale as a potential measure of global disability in early Parkinson’s disease. J Clin Neurosci. 2013;20:1200–1203.
   PubMed Web of Science ®Google Scholar
• Pistacchi M, Gioulis M, Sanson F, et al. Gait analysis and clinical correlations in early Parkinson’s disease. Funct Neurol. 2017;32:28–34.
   PubMed Web of Science ®Google Scholar
• Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80:276–281.
   PubMed Web of Science ®Google Scholar
• Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry. 2013;84:14–17.
   PubMed Web of Science ®Google Scholar
• Ongre SO, Larsen JP, Tysnes OB, et al. Fatigue in early Parkinson’s disease: the Norwegian ParkWest study. Eur J Neurol. 2017;24:105–111.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Lyons KE, Hauser RA, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:142–148.
   PubMed Web of Science ®Google Scholar
• Zis P, Erro R, Walton CC, et al. The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis. 2015;1:15013.
   PubMed Web of Science ®Google Scholar
• Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29:195–202.
   PubMed Web of Science ®Google Scholar
• Giladi N, Asgharnejad M, Bauer L, et al. Rotigotine in combination with the MAO-B inhibitor selegiline in early Parkinson’s disease: a post hoc analysis. J Parkinsons Dis. 2016;6:401–411.
   PubMedGoogle Scholar
• Luquin MR, Kulisevsky J, Martinez-Martin P, et al. Consensus on the definition of advanced Parkinson’s disease: a neurologists-based Delphi study (CEPA study). Parkinsons Dis. 2017;2017:4047392.
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129–2170.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19:1020–1028.
   PubMed Web of Science ®Google Scholar
• Martínez-Martín P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson’s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord. 1994;9:76–83.
   PubMed Web of Science ®Google Scholar
• Piccini P, Pavese N, Canapicchi R, et al. White matter hyperintensities in Parkinson’s disease. Clinical correlations. Arch Neurol. 1995;52:191–194.
   PubMedGoogle Scholar
• Schrag A, Selai C, Jahanshahi M, et al. The EQ-5D–a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000;69:67–73.
   PubMed Web of Science ®Google Scholar
• Marinus J, Visser M, Stiggelbout AM, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry. 2004;75:388–395.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Prieto L, Forjaz MJ. Longitudinal metric properties of disability rating scales for Parkinson’s disease. Value Health. 2006;9:386–393.
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Lai Y-Y, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain. 2007;130:1586–1595.
   PubMed Web of Science ®Google Scholar
• Maetzler W, Liepelt I, Berg D. Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol. 2009;8:1158–1171.
   PubMed Web of Science ®Google Scholar
• Yagi S, Yoshikawa E, Futatsubashi M, et al. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET. J Nucl Med. 2010;51:1250–1257.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol. 2013;260:228–236.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, et al. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:889–893.
   PubMed Web of Science ®Google Scholar
• Hsiao IT, Weng YH, Hsieh CJ, et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014;71:758–766.
   PubMed Web of Science ®Google Scholar
• Yildiz D, Erer S, Zarifoğlu M, et al. Impaired cognitive performance and hippocampal atrophy in Parkinson disease. Turk J Med Sci. 2015;45:1173–1177.
   PubMed Web of Science ®Google Scholar
• Wu G, Shen Y-J, Huang M-H, et al. Proton MR Spectroscopy for monitoring pathologic changes in the substantia nigra and globus pallidus in Parkinson disease. AJR Am J Roentgenol. 2016;206:385–389.
   PubMed Web of Science ®Google Scholar
• Skorvanek M, Martinez-Martin P, Kovacs N, et al. Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration. Mov Disord-Clin Practice. 2017;4:536–544.
   Web of Science ®Google Scholar
• Sauerbier A, Qamar MA, Rajah T, et al. New concepts in the pathogenesis and presentation of Parkinson’s disease. Clin Med (Lond). 2016;16:365–370.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Forjaz MJ, Cubo E, et al. Global versus factor-related impression of severity in Parkinson’s disease: a new clinimetric index (CISI-PD). Mov Disord. 2006;21:208–214.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. The clinical impression of severity index for Parkinson’s disease: international validation study. Mov Disord. 2009;24:211–217.
   PubMed Web of Science ®Google Scholar
• Armañanzas R, Bielza C, Chaudhuri KR, et al. Unveiling relevant non-motor Parkinson’s disease severity symptoms using a machine learning approach. Artif Intell Med. 2013;58:195–202.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Abe K, et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology. 2009;73:1584–1591.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Falup Pecurariu C, Odin P, et al. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. J Neurol. 2012;259:1639–1647.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, et al. Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS scale. Eur J Neurol. 2015;22:37–43.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30:510–516.
   PubMed Web of Science ®Google Scholar
• Dafsari HS, Reddy P, Herchenbach C, et al. Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson’s disease. Brain Stimul. 2016;9:78–85.
   PubMed Web of Science ®Google Scholar
• Kurtis MM, Rajah T, Delgado LF, et al. The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence. NPJ Parkinsons Dis. 2017;3:16024.
   PubMedGoogle Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord. 2007;22:1623–1629.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Violante M, Cervantes-Arriaga A, Villar-Velarde A, et al. Prevalence of non-motor dysfunction among Parkinson’s disease patients from a tertiary referral center in Mexico City. Clin Neurol Neurosurg. 2010;112:883–885.
   PubMed Web of Science ®Google Scholar
• Crosiers D, Pickut B, Theuns J, et al. Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson’s disease patients as assessed by the Non-Motor Symptoms Questionnaire. Am J Neurodegener Dis. 2012;1:160–167.
   PubMedGoogle Scholar
• National Institute of Clinical Excellence (NICE). Parkinson’s disease in adults. NICE guidelines, Published 19 July 2017. 23 p. Available from: Nice.org.uk/guidance/ng71.
   Google Scholar
• Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson’s disease. Vol. 2. Florham Park (NJ): Macmillan Healthcare Information; 1987. p. 153–164.
   Google Scholar
• Movement Disorder Society Task Force on Rating Scales for Parkinson’s disease. UPDRS: status and recommendations. Mov Disord. 2003;18:738–750.
   PubMed Web of Science ®Google Scholar
• Antonini A, Abbruzzese G, Ferini-Strambi L, et al. Validation of the Italian version of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale. Neurol Sci. 2013;34:683–687.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Stebbins GT, Wang L, et al. IPMDS-sponsored scale translation program: process, format, and clinimetric testing plan for the MDS-UPDRS and UDysRS. Mov Disord Clin Pract. 2014;1:97–101.
   PubMedGoogle Scholar
• International Parkinson and Movement Disorder Society. [ cited 2017 Aug 11]. Available from: http://www.movementdisorders.org/MDS/Education/Rating-Scales.htm.
   Google Scholar
• Verbaan D, Van Rooden SM, Benit CP, et al. SPES/SCOPA and MDS-UPDRS: formulas for converting scores of two motor scales in Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:632–634.
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Goetz CG, Stebbins G, et al. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson’s disease. Mov Disord. 2012;27:79–83.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Stebbins GT, Tilley BC. Calibration of unified Parkinson’s disease rating scale scores to movement disorder society-unified Parkinson’s disease rating scale scores. Mov Disord. 2012;27:1239–1242.
   PubMed Web of Science ®Google Scholar
• Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov Disord. 2013;28:668–670.
   PubMed Web of Science ®Google Scholar
• Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, et al. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson’s disease patients. Eur J Neurol. 2014;21:519–524.
   PubMed Web of Science ®Google Scholar
• Jafari N, Pahwa R, Nazzaro JM, et al. MDS-UPDRS to assess non-motor symptoms after STN DBS for Parkinson’s disease. Int J Neurosci. 2016;126:25–29.
   PubMed Web of Science ®Google Scholar
• SCOPA scales. [ cited 2017 Oct 18]. Available from: https://www.lumc.nl/org/neurologie/research/propark-research/Scales/?setlanguage=English&setcountry=en.
   Google Scholar
• Ba F, Obaid M, Wieler M, et al. Parkinson disease: the relationship between non-motor symptoms and motor phenotype. Can J Neurol Sci. 2016;43:261–267.
   PubMed Web of Science ®Google Scholar
• Fereshtehnejad S-M, Postuma RB. Subtypes of Parkinson’s disease: what do they tell us about disease progression? Curr Neurol Neurosci Rep. 2017;17:34.
   PubMed Web of Science ®Google Scholar
• Marras C, Chaudhuri KR. Nonmotor features of Parkinson’s disease subtypes. Mov Disord. 2016;31:1095–1102.
   PubMed Web of Science ®Google Scholar
• Mu J, Chaudhuri KR, Bielza C, et al. Parkinson’s disease subtypes identified from cluster analysis of motor and non-motor symptoms. Front Aging Neurosci. 2017;20;9:301.
   Web of Science ®Google Scholar